AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

Drug approval Earnings report AI-generated analysis

📈 AbbVie shares have rallied 28.55% year-to-date ahead of the October 30 earnings report, with options pricing a roughly 5% swing on the release.

💊 Skyrizi revenue grew 24.4% to $5.51 billion while Rinvoq rose 24.5% to $2.53 billion, nearly half of total revenue.

📉 Humira sales slid 35.9%, but strong immunology growth more than compensated for the decline in the last quarter.

🔬 The FDA approved Juvmo (tavapadon) for Parkinson's disease and Skyrizi's subcutaneous induction regimen for Crohn's disease recently.

💰 Management trimmed full-year adjusted EPS guidance to $13.87-$14.07 due to $0.14 per share dilution from the Apogee Therapeutics deal.

📊 Revenue guidance was raised by $300 million to approximately $67.6 billion for the full year.

🧠 Neuroscience revenue grew 20.3% to $3.23 billion, with Vyalev expected to reach blockbuster sales this year.

⚠️ Recent history shows shares fell 4.45% and 2.51% on earnings days after beating estimates in Q3 2025 and Q2 2026 respectively.

📉 Imbruvica sales fell 29.4% and Juvederm slipped 6.0% in the second quarter, adding pressure to top-line growth.

🎯 Analyst consensus EPS of $3.78 sits below management's target of $3.84-$3.88 after eight downward revisions over 30 days.

Bullish Signals
  • Skyrizi revenue grew 24.4% to $5.51 billion and Rinvoq rose 24.5% to $2.53 billion, generating nearly half of total company revenue.
  • The FDA approved Juvmo for Parkinson's disease and Skyrizi's subcutaneous induction regimen for Crohn's disease, expanding the pipeline.
  • Revenue guidance was raised by $300 million to about $67.6 billion despite trimming EPS guidance due to acquisition costs.
  • Neuroscience revenue grew 20.3% to $3.23 billion last quarter with Vyalev expected to become a blockbuster this year.
  • Management reported "absolutely no degradation" in Skyrizi new starts following the launch of a rival product.
Risk Factors
  • Management trimmed full-year adjusted EPS guidance to $13.87-$14.07 due to $0.14 per share dilution from the Apogee Therapeutics deal.
  • Humira sales slid 35.9% in the last quarter, and the pace of erosion still determines how much immunology gain reaches the top line.
  • Imbruvica sales fell 29.4% and Juvederm slipped 6.0% in the second quarter, creating drag on overall revenue growth.
  • The stock has a recent habit of selling off even after beating estimates, falling 4.45% and 2.51% on previous earnings days.
  • Analyst consensus EPS of $3.78 sits below management's target of $3.84-$3.88 following eight downward revisions over the past 30 days.
Full Analysis
AbbVie (ABBV) is approaching its October 30 earnings report with shares up 28.55% year-to-date, though options pricing suggests a volatile 5% swing in either direction. The stock has historically sold off even after beating estimates, as seen in previous quarters where it fell despite positive results, indicating that management's guidance is critical for sustaining the rally. Financially, AbbVie's immunology portfolio remains robust with Skyrizi and Rinvoq generating nearly half of total revenue. Skyrizi grew 24.4% to $5.51 billion and Rinvoq rose 24.5% to $2.53 billion in the last quarter, effectively offsetting a significant 35.9% decline in Humira sales. The company recently received FDA approvals for Juvmo for Parkinson's disease and a new subcutaneous induction regimen for Skyrizi in Crohn's disease. Despite strong product performance, AbbVie trimmed its full-year adjusted EPS guidance to $13.87-$14.07 due to dilution from the Apogee Therapeutics acquisition, which costs roughly $0.14 per share. Analysts expect a sharp profit rebound in the upcoming quarter as the year-ago period included a one-time $1.50 acquired IPR&D charge. The company trades near 20x full-year consensus EPS, and investors will be watching for confirmation that operational strength offsets the drag from the Apogee deal.